Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 12, 2018. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing text does not provide company-wide financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to specific share transactions:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Price: £13.4317 per share.
- Transaction Volume: Ranged from 18 to 20 shares per individual executive.
Material Changes
The filing does not report material changes to the company's financial position or operations. It strictly documents the acquisition of shares by executives under the Company's Share Reward Plan on March 9, 2018, executed on the London Stock Exchange (XLON).
Guidance, Outlook, and Risks
The filing text does not contain management commentary, forward-looking guidance, risk factors, contingencies, or unusual items. The document is a regulatory disclosure of specific equity transactions.
Important Facts for Investor Verification
- Executive Participation: Nine senior executives participated in the Share Reward Plan, including CEO Emma Walmsley, CFO Simon Dingemans, and President of R&D Peter Vallance.
- Transaction Nature: All transactions were acquisitions of ordinary shares, split between "partnership shares" and "matching shares."
- Timing: All reported transactions occurred on the same date: March 9, 2018.
- Share Count: Most executives acquired 20 shares total (10 partnership + 10 matching), while Peter Thomson and Peter Vallance acquired 18 shares total (9 partnership + 9 matching).